29/08/2015 12:59:35 Free Membership Login

Immupharma News (LSE:IMM)

DateTimeSource
Headline
07/29/20155:16AMALNCImmuPharma Says Chairman And Co-Founder Richard Warr Dies
LONDON (Alliance News) - Specialist drug development and discovery company ImmuPharma PLC said Wednesday that Chairman Richard Warr died late last week. "No words can truly convey the deep sadness we feel at Richard's untimely passing away. Richard will be remembered and missed by all of us at ImmuPharma. As a co-founder... More...>>
07/27/20153:08AMALNCImmuPharma Secures Financing To Continue Lupuzor Progress (ALLISS)
LONDON (Alliance News) - Drug discovery and development company ImmuPharma PLC on Monday said its registration for Lupuzor has gone live and said it has signed a term sheet to fund the clinical trial of the product. Lupuzor is ImmuPharma's lupus treatment. The registration for the company on the US National Institutes... More...>>
06/25/20152:00AMRNSNONImmupharma PLC Lupuzor's Founder Dr Slyviane Muller Awarded Medal
TIDMIMM RNS Number : 1580R Immupharma PLC 25 June 2015 ImmuPharma PLC 25 JUNE 2015 Lupuzor's Founder, Dr Slyviane Muller - Awarded Medal of Innovation from CNRS for Lupuzor(TM) ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is delighted to announce that... More...>>
05/06/20154:11AMALNCImmuPharma Chairman Takes Leave To Deal With Health Issue
LONDON (Alliance News) - ImmuPharma PLC Wednesday said Senior Non-Executive Director Franco Di Muzio will become its interim chairman after Executive Chairman Richard Warr took leave to make a full recovery from recent ill health. "As the senior non-executive director of ImmuPharma since its formation, I have an in-depth... More...>>
04/30/20155:37AMALNCImmupharma To Focus On Lupuzor, 2014 Loss Narrows On Trial End
LONDON (Alliance News) - Immupharma PLC Thursday said it will continue to focus on bringing its potential treatment for lupus Lupuzor to commercialisation, and posted a narrowed loss for 2014 due to a clinical trial completing. The drug discovery and development company posted a pretax loss of GBP3.3 million for 2014... More...>>
02/11/20157:18AMALNCImmupharma Says Cancer Therapy Trial Meets Primary Objective
LONDON (Alliance News) - Immupharma PLC said Wednesday that a phase I/IIa clinical trial of its cancer programme IPP-204106 met its primary objective, and it will now commence a phase II study in pancreatic cancer. The phase I/IIa trial was a dose-finding adaptive study, and the results showed that the maximum tolerated... More...>>
01/22/20153:32AMALNCImmuPharma Shares Up 22% On Simbec-Orion Lupuzor Agreement
LONDON (Alliance News) - Shares in ImmuPharma PLC are trading up 22% Thursday morning after it said it has entered an agreement with Simbec-Orion Group Ltd to begin a phase III study of ImmuPharma's Lupuzor treatment for lupus and will get an investment from the company. Simbec-Orion has agreed it will reinvest a significant... More...>>
10/20/20142:59AMALNCImmuPharma Gets EUR400,000 Grant In France For Urelix Technology
LONDON (Alliance News) - ImmuPharma PLC Monday said the French region of Acquitane in the Bordeaux region of the country has awarded its Ureka subsidiary with a EUR400,000 grant. The funding has been awarded to the company's subsidiary to develop its Urelix technology, which mimics natural peptides having a helical conformation... More...>>
09/30/20145:27AMALNCImmuPharma Poised For Phase III Trials Of Lupuzor As Loss As Expected
LONDON (Alliance News) - ImmuPharma PLC Tuesday said its key compound, lupus treatment Lupuzor, will soon enter phase III trials as it posted an in-line pretax loss for the half year to end-June. The company posted a pretax loss of GBP1.8 million, broadly flat on the previous year as it maintained its level of operating... More...>>
05/06/20147:47AMRNSNONImmupharma PLC Dr. Sylviane Muller - Presentation Abstract
TIDMIMM RNS Number : 3468G Immupharma PLC 06 May 2014 FOR IMMEDIATE RELEASE RNS REACH* 6 MAY 2014 Dr. Sylviane Muller - Presentation Abstract from 2014 European Lupus Conference ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides a summary of the presentation... More...>>
04/23/20142:00AMRNSNONImmupharma PLC Dr. S Muller, founder of Lupuzor presentation.
TIDMIMM RNS Number : 2687F Immupharma PLC 23 April 2014 FOR IMMEDIATE RELEASE RNS REACH 23 APRIL 2014 Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announced that... More...>>
04/11/20142:00AMRNSNONImmupharma PLC ImmuPharma Sponsors the 2014 European Lupus Confer
TIDMIMM RNS Number : 5939E Immupharma PLC 11 April 2014 FOR IMMEDIATE RELEASE RNS REACH 11 APRIL 2014 ImmuPharma Sponsors the 2014 European Lupus Conference Presentation Date: 24 April 2014 ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm... More...>>
07/08/20133:00AMRNSNONImmupharma PLC IMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
TIDMIMM RNS Number : 7772I Immupharma PLC 08 July 2013 8 July 2013 ImmuPharma PLC IMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS TO SCIENTIFIC ADVISORY BOARD FOR LUPUZOR PHASE III ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group"), the specialist drug discovery and development company, is delighted... More...>>
02/28/20132:02AMRNSNONImmupharma PLC ImmuPharma Commences Trading on Stuttgart Exchange
TIDMIMM RNS Number : 8448Y Immupharma PLC 28 February 2013 FOR IMMEDIATE RELEASE 28 FEBRUARY 2013 RNS REACH ImmuPharma PLC Commences Trading on the Stuttgart Stock Exchange ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announces that it... More...>>
01/28/20134:33AMRNSNONImmupharma PLC CNRS Confirms Lupuzor's (TM) Effectiveness
TIDMIMM RNS Number : 4761W Immupharma PLC 28 January 2013 FOR IMMEDIATE RELEASE 28 JANUARY 2013 RNS REACH CNRS Confirms Lupuzor's (TM) Effectiveness ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration... More...>>
11/05/20122:00AMRNSNONImmupharma PLC Lupuzor Presentation
TIDMIMM RNS Number : 2719Q Immupharma PLC 05 November 2012 FOR IMMEDIATE RELEASE 5 NOVEMER 2012 RNS REACH ImmuPharma to Present Lupuzor(TM) Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Presentation Date: 14 November 2012 ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the... More...>>
09/07/20126:12AMRNSNONImmupharma PLC Rodman and Renshaw Conference
TIDMIMM RNS Number : 7713L Immupharma PLC 07 September 2012 FOR IMMEDIATE RELEASE 7 SEPTEMBER 2012 RNS REACH ImmuPharma to Present at Rodman and Renshaw Annual Global Investment Conference, New York Tuesday 11 September 2012 ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse imm150829 12:59